Evidence mapPaperPMID 32961682Full record

ReviewInternational journal of molecular sciences2020

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Roberto Grigolato, Maria Eleonora Bizzoca, Luca Calabrese, Stefania Leuci, Michele Davide Mignogna, Lorenzo Lo Muzio

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Oral Health and Nutraceutical Agents.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Roberto GrigolatoDivision of Prevention, San Maurizio Hospital, 39100 Bolzano, Italy.
Maria Eleonora BizzocaDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0002-6722-6499
Luca CalabreseDivision of Otorhinolaryngology, "San Maurizio" Hospital, 39100 Bolzano, Italy.ORCID 0000-0001-6476-3689
Stefania LeuciDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, Oral Medicine Unit, Federico II University of Naples, 80138 Naples, Italy.ORCID 0000-0003-4468-5083
Michele Davide MignognaDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, Oral Medicine Unit, Federico II University of Naples, 80138 Naples, Italy.
Lorenzo Lo MuzioDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0003-4633-4893
Ospedale di Bolzano · ITUniversity of Foggia · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations frequently characterized by an architectural and cytological derangements upon histological analysis. Among them, oral leukoplakia is the most common type of these disorders. This work aims to analyze the possible use of drugs such as immunochemopreventive agents for OPMDs. Chemoprevention is the use of synthetic or natural compounds for the reversal, suppression, or prevention of a premalignant lesion conversion to malignant form. Experimental and in vivo data offer us the promise of molecular prevention through immunomodulation; however, currently, there is no evidence for the efficacy of these drugs in the chemoprevention action. Alternative ways to deliver drugs, combined use of molecules with complementary antitumor activities, diet influence, and better definition of individual risk factors must also be considered to reduce toxicity, improve compliance to the protocol treatment and offer a better individualized prevention. In addition, we must carefully reconsider the mode of action of many traditional cancer chemoprevention agents on the immune system, such as enhancing immunosurveillance and reversing the immune evasion. Several studies emphasize the concept of green chemoprevention as an alternative approach to accent healthy lifestyle changes in order to decrease the incidence of HNSCC.

Indexed as

Leukoplakia, OralMouth NeoplasmsAnticarcinogenic AgentsHumansAnticarcinogenic AgentscancerchemopreventionHNSCCimmunologyLeukoplakiaOPMDs

Identifiers

PMID32961682
PMCPMC7555729
OpenAlexW3087524139

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.